Build Your Comparison

Side-by-side financial analysis
NCRA logo
NCRA
LIXT logo
LIXT
ONCY logo
ONCY
RELI logo
RELI
KO logo
KO
Try popular comparisons:

Stock Comparison

NCRA vs LIXT vs ONCY vs RELI vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NCRA
Nocera, Inc.

Packaged Foods

Consumer DefensiveNASDAQ • TW
Market Cap$2M
5Y Perf.-96.3%
LIXT
Lixte Biotechnology Holdings, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$76M
5Y Perf.-77.0%
ONCY
Oncolytics Biotech Inc.

Biotechnology

HealthcareNASDAQ • CA
Market Cap$94M
5Y Perf.-66.6%
RELI
Reliance Global Group, Inc.

Insurance - Brokers

Financial ServicesNASDAQ • US
Market Cap$554K
5Y Perf.-100.0%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$342.09B
5Y Perf.+65.1%

NCRA vs LIXT vs ONCY vs RELI vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NCRA logoNCRA
LIXT logoLIXT
ONCY logoONCY
RELI logoRELI
KO logoKO
IndustryPackaged FoodsBiotechnologyBiotechnologyInsurance - BrokersBeverages - Non-Alcoholic
Market Cap$2M$76M$94M$554K$342.09B
Revenue (TTM)$11M$0.00$0.00$13M$49.28B
Net Income (TTM)$-4M$-7M$-35M$-7M$13.70B
Gross Margin1.4%-14.5%61.7%
Operating Margin-25.2%-66.3%29.3%
Forward P/E24.3x
Total Debt$7M$664K$773K$13M$45.49B
Cash & Equiv.$8M$5M$7M$373K$10.27B

NCRA vs LIXT vs ONCY vs RELI vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NCRA
LIXT
ONCY
RELI
KO
StockJan 21Jun 26Return
Nocera, Inc. (NCRA)1003.7-96.3%
Lixte Biotechnology… (LIXT)10023.0-77.0%
Oncolytics Biotech … (ONCY)10033.4-66.6%
Reliance Global Gro… (RELI)1000.0-100.0%
The Coca-Cola Compa… (KO)100165.1+65.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: NCRA vs LIXT vs ONCY vs RELI vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LIXT and KO are tied at the top with 3 categories each (5-stock set) — the right choice depends on your priorities. The Coca-Cola Company is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
NCRA
Nocera, Inc.
The Consumer Defensive Pick

NCRA plays a supporting role in this comparison — it may shine differently against other peers.

Best for: consumer defensive exposure
LIXT
Lixte Biotechnology Holdings, Inc.
The Income Pick

LIXT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.19
  • Lower volatility, beta 1.19, Low D/E 6.1%, current ratio 3.88x
  • Beta 1.19, current ratio 3.88x
  • 152.8% revenue growth vs ONCY's -65.0%
Best for: income & stability and sleep-well-at-night
ONCY
Oncolytics Biotech Inc.
The Healthcare Pick

ONCY lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
RELI
Reliance Global Group, Inc.
The Insurance Pick

RELI is the clearest fit if your priority is growth exposure.

  • Rev growth 2.3%, EPS growth 11.9%, 3Y rev CAGR 13.1%
Best for: growth exposure
KO
The Coca-Cola Company
The Long-Run Compounder

KO is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 112.9% 10Y total return vs LIXT's -22.2%
  • 27.8% margin vs RELI's -53.4%
  • 2.6% yield; 56-year raise streak; the other 4 pay no meaningful dividend
  • 13.1% ROA vs ONCY's -275.4%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthLIXT logoLIXT152.8% revenue growth vs ONCY's -65.0%
Quality / MarginsKO logoKO27.8% margin vs RELI's -53.4%
Stability / SafetyLIXT logoLIXTBeta 1.19 vs NCRA's 1.68, lower leverage
DividendsKO logoKO2.6% yield; 56-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)LIXT logoLIXT+407.2% vs NCRA's -83.7%
Efficiency (ROA)KO logoKO13.1% ROA vs ONCY's -275.4%

NCRA vs LIXT vs ONCY vs RELI vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NCRANocera, Inc.

Segment breakdown not available.

LIXTLixte Biotechnology Holdings, Inc.

Segment breakdown not available.

ONCYOncolytics Biotech Inc.

Segment breakdown not available.

RELIReliance Global Group, Inc.
FY 2020
Property and Casualty
100.0%$1M
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

NCRA vs LIXT vs ONCY vs RELI vs KO — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGONCY

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 5 of 6 comparable metrics.

KO and ONCY operate at a comparable scale, with $49.3B and $0 in trailing revenue. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to RELI's -53.4%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$11M$0$0$13M$49.3B
EBITDAEarnings before interest/tax-$3M-$7M-$31M-$7M$15.5B
Net IncomeAfter-tax profit-$4M-$7M-$35M-$7M$13.7B
Free Cash FlowCash after capex-$3M-$4M-$29M-$2M$12.6B
Gross MarginGross profit ÷ Revenue+1.4%-14.5%+61.7%
Operating MarginEBIT ÷ Revenue-25.2%-66.3%+29.3%
Net MarginNet income ÷ Revenue-34.0%-53.4%+27.8%
FCF MarginFCF ÷ Revenue-26.9%-18.1%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year-49.8%-27.5%+12.1%
EPS Growth (YoY)Latest quarter vs prior year-3.9%+37.9%-39.2%+70.1%+18.2%
KO leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

RELI leads this category, winning 2 of 3 comparable metrics.
MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…KO logoKOThe Coca-Cola Com…
Market CapShares × price$2M$76M$94M$553,552$342.1B
Enterprise ValueMkt cap + debt − cash$2M$72M$89M$13M$377.3B
Trailing P/EPrice ÷ TTM EPS-0.84x-5.56x-2.83x-0.03x26.14x
Forward P/EPrice ÷ next-FY EPS est.24.31x
PEG RatioP/E ÷ EPS growth rate2.34x
EV / EBITDAEnterprise value multiple25.47x
Price / SalesMarket cap ÷ Revenue0.22x0.04x7.14x
Price / BookPrice ÷ Book value/share1.09x30.91x0.08x10.00x
Price / FCFMarket cap ÷ FCF64.59x
RELI leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 6 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-102 for ONCY. LIXT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to RELI's 4.35x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs ONCY's 1/9, reflecting strong financial health.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-132.0%-113.2%-102.5%-181.4%+41.1%
ROA (TTM)Return on assets-52.5%-96.3%-2.8%-41.3%+13.1%
ROICReturn on invested capital-70.0%-121.5%-32.0%+15.8%
ROCEReturn on capital employed-35.9%-83.5%-5.1%-45.9%+17.3%
Piotroski ScoreFundamental quality 0–934147
Debt / EquityFinancial leverage3.31x0.06x4.35x1.33x
Net DebtTotal debt minus cash-$697,307-$4M-$6M$13M$35.2B
Cash & Equiv.Liquid assets$8M$5M$7M$372,695$10.3B
Total DebtShort + long-term debt$7M$664,491$772,509$13M$45.5B
Interest CoverageEBIT ÷ Interest expense-1217.29x-4.90x10.70x
KO leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

KO leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $15,855 today (with dividends reinvested), compared to $3 for RELI. Over the past 12 months, LIXT leads with a +407.2% total return vs NCRA's -83.7%. The 3-year compound annual growth rate (CAGR) favors KO at 12.0% vs RELI's -84.8% — a key indicator of consistent wealth creation.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-80.3%+82.3%-14.7%-54.3%+15.8%
1-Year ReturnPast 12 months-83.7%+407.2%+151.3%-81.7%+15.0%
3-Year ReturnCumulative with dividends-88.7%+5.6%-49.0%-99.6%+40.5%
5-Year ReturnCumulative with dividends-96.6%-77.3%-72.0%-100.0%+58.5%
10-Year ReturnCumulative with dividends-97.4%-22.2%-79.6%-100.0%+112.9%
CAGR (3Y)Annualised 3-year return-51.6%+1.8%-20.1%-84.8%+12.0%
KO leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.15 beta — it tends to amplify market swings less than NCRA's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 96.1% from its 52-week high vs RELI's 6.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5001.68x1.19x1.24x1.35x-0.15x
52-Week HighHighest price in past year$2.40$7.50$1.51$3.55$82.66
52-Week LowLowest price in past year$0.16$0.64$0.33$0.15$65.35
% of 52W HighCurrent price vs 52-week peak+7.0%+93.3%+55.4%+6.9%+96.1%
RSI (14)Momentum oscillator 0–10040.869.846.242.937.7
Avg Volume (50D)Average daily shares traded7.2M89K1.3M2.9M12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: ONCY as "Buy", KO as "Buy". KO is the only dividend payer here at 2.56% yield — a key consideration for income-focused portfolios.

MetricNCRA logoNCRANocera, Inc.LIXT logoLIXTLixte Biotechnolo…ONCY logoONCYOncolytics Biotec…RELI logoRELIReliance Global G…KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$86.29
# AnalystsCovering analysts1048
Dividend YieldAnnual dividend ÷ price+2.6%
Dividend StreakConsecutive years of raises0056
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+0.2%
KO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

KO leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RELI leads in 1 (Valuation Metrics).

Best OverallThe Coca-Cola Company (KO)Leads 5 of 6 categories
Loading custom metrics...

NCRA vs LIXT vs ONCY vs RELI vs KO: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is NCRA or LIXT or ONCY or RELI or KO a better buy right now?

For growth investors, Reliance Global Group, Inc.

(RELI) is the stronger pick with 2. 3% revenue growth year-over-year, versus -35. 2% for Nocera, Inc. (NCRA). The Coca-Cola Company (KO) offers the better valuation at 26. 1x trailing P/E (24. 3x forward), making it the more compelling value choice. Analysts rate Oncolytics Biotech Inc. (ONCY) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — NCRA or LIXT or ONCY or RELI or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +58.

5%, compared to -100. 0% for Reliance Global Group, Inc. (RELI). Over 10 years, the gap is even starker: KO returned +112. 9% versus RELI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — NCRA or LIXT or ONCY or RELI or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

15β versus Nocera, Inc. 's 1. 68β — meaning NCRA is approximately -1234% more volatile than KO relative to the S&P 500. On balance sheet safety, Lixte Biotechnology Holdings, Inc. (LIXT) carries a lower debt/equity ratio of 6% versus 4% for Reliance Global Group, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — NCRA or LIXT or ONCY or RELI or KO?

By revenue growth (latest reported year), Reliance Global Group, Inc.

(RELI) is pulling ahead at 2. 3% versus -35. 2% for Nocera, Inc. (NCRA). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -11. 1% for Nocera, Inc.. Over a 3-year CAGR, RELI leads at 13. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — NCRA or LIXT or ONCY or RELI or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -64. 5% for Reliance Global Group, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -54. 8% for RELI. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — NCRA or LIXT or ONCY or RELI or KO?

In this comparison, KO (2.

6% yield) pays a dividend. NCRA, LIXT, ONCY, RELI do not pay a meaningful dividend and should not be held primarily for income.

07

Is NCRA or LIXT or ONCY or RELI or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

15), 2. 6% yield, +112. 9% 10Y return). Nocera, Inc. (NCRA) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +112. 9%, NCRA: -97. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between NCRA and LIXT and ONCY and RELI and KO?

These companies operate in different sectors (NCRA (Consumer Defensive) and LIXT (Healthcare) and ONCY (Healthcare) and RELI (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

KO pays a dividend while NCRA, LIXT, ONCY, RELI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.